JOHNSON & JOHNSON is 159.5x more valuable than Crinetics Pharmaceuticals, Inc. by market capitalization ($579.83 B vs $3.63 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CRNX | JNJ |
|---|---|---|
| Market cap | $3.63 B | $579.83 B |
| US-listed rank | #1665 | #20 |
| Revenue (latest FY) | $7.70M | $94.19B |
| Net income (latest FY) | -$465.30M | $26.80B |
| Net margin | -6046.0% | 28.5% |
| P/E (trailing FY) | - | 21.6 |
| SEC filings | 670 | 984 |
JOHNSON & JOHNSON is 159.5x more valuable than Crinetics Pharmaceuticals, Inc. by market capitalization ($579.83 B vs $3.63 B).
In their latest fiscal years, Crinetics Pharmaceuticals, Inc. reported $7.70M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Crinetics Pharmaceuticals, Inc. and JOHNSON & JOHNSON, or browse the full rankings.